Your email has been successfully added to our mailing list.

×
0.0314136125654449 -0.0785340314136126 -0.0680628272251309 -0.0890052356020943 -0.162303664921466 -0.130890052356021 -0.104712041884817 -0.0984293193717278
Stock impact report

PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency

PHASERX (PZRX) 
US:NASDAQ Investor Relations: investor.phaserx.com/investors/default.aspx
Company Research Source: PR Newswire
SEATTLE, April 25, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal product (orphan drug) designation for PRX-OTC for the treatment of ornithine transcarbamylase deficiency (OTCD). OTCD is a rare genetic disorder characterized by a complete or partial lack of the enzyme ornithine transcarbamylase, an essential urea cycle enzyme that facilitates the break down and removal of ammonia from the body. "This positive opinion recommending orphan drug designation for PRX-OTC in the European Union represents another important step forward towards potentially bringing this novel therapy to patients that suffer from the devastating effects of OTCD," said Robert W. Overell, Ph.D., president and c Show less Read more
Impact Snapshot
Event Time:
PZRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for PZRX alerts
Opt-in for
PZRX alerts

from News Quantified
Opt-in for
PZRX alerts

from News Quantified